Jörg Knäblein / Rainer H. Müller (Hgg.)

Modern Biopharmaceuticals

Design, Development and Optimization
Ed. by Rainer H. Müller and Jörg Knäblein

• Gebundenes Buch

Produktbeschreibung

Due to the impressive accumulation of out-standing results, presented by brilliant, privileged and creative thinkers, this unique book reads like the 'Who is Who' of biotechnology. Never before has such an impressive group of individuals contributed to one biotechnology book, including Nobel Prize laureates Robert Huber, Thomas R.

---

The biopharmaceutical market has come along way since 1982 when the first biopharmaceutical product, recombinant human insulin, was launched.
Over 120 such products are currently being marketed around the world including nine blockbuster drugs. The global market for biopharmaceuticals, which is currently valued at US$41 billion, has been growing at an impressive compound annual growth rate of 21% over the previous five years.

With over one third of all pipe-line products in active development are biopharmaceuticals, this segment is set to continue outperforming the total pharmaceutical market and could easily reach US$100 billion by the end of this decade.

Produktdetails

• Verlag: Wiley-VCH
• 1. Auflage
• Seitenzahl: 1886
• Englisch
• Abmessung: 240mm x 122mm
• Gewicht: 4455g
• ISBN-13: 9783527311842
• ISBN-10: 352731184X
• Artikelnr.: 13336846

Autorenporträt

Dr. Jrg Knblein studied Biotechnology / Chemical Engineering at the Society for Biotechnology Research (GBF) in Braunschweig, Germany and Biochemistry at the Max-Planck-Institute for Biochemistry. He received his Ph.D. from the Max-Planck-Institute for Biochemistry in Martinsried / Munich where he worked in the group of Professor Huber (Nobelprize laureate in 1988).

AWARDS:
Riedel-de Haen-Stiftung
Government / Ministry of Science
Nomination for the Max-Buchner-Award from DECHEMA (Society for Biotechnology and Chemical Engineering)
Winner of the McKinsey business plan contest

Inhaltsangabe

Volume 1: Molecular Medicine and Protein Engineering

MODERN BIOPHARMACEUTICALS
- Setting the tone: preface from Nobelprize Laureate Prof. R. Huber
- History, current and future: definition & scope - where do we come from and where will we go

MOLECULAR MEDICINE

SNPs analysis: general ethical aspects and the Estonian Genome Project
- Individualized medicine: benefits, challenges and the healthcare sector - interdependencies
- Genomics-based biopharmaceuticals: turning the genome into drugs
- Gene therapy and retro elements for construction of sophisticated vectors
- Gene pill: harnessing the body's protein production
- Adenovirus-based gene therapy entering phase III
- Genetic vaccination as prevention against AIDS, hepatitis and cancer
- Cell therapy: spheramine - a brain implant for treating Parkinson's disease
- Fighting cancer by selectively starving the cells
- Knock-out mice as disease models and to discover true physiological gene functions

PROTEIN DESIGN
- Enzyme optimization: modifying selectivity, stability, kinetics and characteristics
- Combining tailored in vitro selection strategies based on ribosome display with in vitro diversification by DNA shuffling
- Antibody design: improved stability and other pharm. properties of different formats
- Humization of antibodies and reduced immunogenicity (e.g. elimination of HAMA)
- Phage display: design of monoclonal antibodies, increasing selectivity and affinity
- Generating muteins: increasing biological activity and solubility

PROTEIN EXPRESSION
- Different alternative expression systems (e.g. Dictyostelium): pros & cons
- Humanized mouse cell line: human gylcosylation combined with high protein expression. G-line is a human-mouse heterohybridoma cell line
- Advanced mammalian (CHO, HEK, 293, BHK, 3T3) expression: Flp-In, T-REx
- Plant systems I: easy downstream - secretion of biopharmaceutical via the roots and high yields with viral vectors
- Plant systems II: human glycosylation - biopharmaceuticals in a GMP moss bioreactor
- Volume 2 Drug Development

FROM SYSTEMIC TO TARGETED APPROACH
- Target specific diagnostics & therapeutics: radiopharmaceuticals - find, fight, follow
- Ligand-based in vivo targeting of disease: from antibody to small organic ligands
- PET imaging: the magic bullet to study cancer and metabolism in real time
- Advanced Drug Delivery Systems

HIGH THROUGHPUT CLONING
- Massive parallel expression of biopharmaceuticals for screening purposes
- Learning from viruses: easy cloning without restriction enzymes (e.g. Gateway)

IN VIVO AND IN VITRO ANALYTICAL METHODS
- Cell-based assays (e.g. GFP)
- Pharmacodynamic / pharmacokinetic, efficacy, side effects and interactions
- IVIV correlation

DOMAIN EXCHANGE BY SHUFFLING AND SWAPPING
- Improving enzymes: Taq Polymerases with proof reading activity etc.
- Metabolic engineering: domain exchange in Polyketide Synthases and how to create new unnatural & complex natural compounds (heterocyclic systems, e.g. epothilon)

CASE STUDY
- Design & approval: Baxter's R&D activities with Recombinate, AntiHemophilic Factor (rAHF) as clotting Factor VIII - essential for more than 300,000 people suffering from hemophilia. History of product development, approval, expansion of production capacities (begin of construction in 1992 until licensing in 1996)

ADVANTAGES OF SMALL MOLECULES
- Back to the past or ahead of the future: in silico ADME predictions class switching from peptide to small molecule lead candidates

ARE INNOVATIVE DRUGS STILL PAYABLE?
- Economical aspects of modern biopharmaceuticals. R&D management in the biotech industry - facing regional challenges and impact of changes in the health systems

Rezensionen

"Der Herausgeber Dr. Jörg Knäblein ist der Leiter der Abteilung Mikrobiologische Chemie bei Schering. Das Werk ist eine einzigartige und umfassende Einführung in die neuere technologische Entwicklung bei Biopharmazeutika, es zeigt die Paradigmenwechsel in der medizinischen Behandlung auf und wie diese Veränderungen auf die industrielle Forschung ausstrahlen. Die Autoren des Werkes kommen aus den weltweit renommiertesten Forschungsinstituten - darunter die Nobelpreisträger Robert Huber und Thomas R. Cech - und Biotechnologie-Unternehmen." - CHEManager

"Das Werk umfasst vier Bände mit allein 80-seitigem Executive Summary. Hier wird das heutige Wissen der modernen Wirkstoffentwicklung aus akademischer und Industrieforschung zusammengeführt. Von Antikörper bis Zulassungsverfahren: Methoden, Mechanismen, Genregulation und Gesundheitspolitik werden von ausgewiesenen Spezialisten detailliert auf dem neuesten Stand dargestellt." - BioRegioN

"...ein umfassendes Bild über den aktuellen Stand der biotechnologischen Entwicklung auf der Basis molekularbiologischer Wissenschaften... Die beigefügte CD zum Buch enthält unter anderem einige beeindruckende Darstellungen aus dem Institut von Dr. Hwang ... Ebenfalls sind die kompletten Inhaltsverzeichnisse in jedem Band hilfreich. ... molekularbiologische Strukturen und Abbildungen in hoher Qualität ... Ein umfassendes Werk und Spiegel der derzeit erfolgreichen Pharma-Branche." - Umwelt und Gesundheit